SAN JOSE, May 12, 2025/ PRNewswire/-- Anixa Biosciences, Inc., a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Pamela D. Garzone, Chief ...

2025 ASCO Presentation: Innovent Biologics Announces Updated Data of IBI354 (Novel anti-HER2 ADC) From the Phase 1/2 Clinical Study in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors ...

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer Imunon, Inc.

IGCS Oral Presentation Details. Title: Efficacy and Safety of Avutometinib + Defactinib in Recurrent Low Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-ov60/GOG-3052/RAMP 201 ...

Presentation at ESMO will follow oral 2025 ASCO Annual Meeting presentation highlighting unprecedented survival data from Phase 2 OVATION 2 Study of IMNN-001 Simultaneously publication in leading ...

Uptake of lipids from ascites drives NK cell metabolic dysfunction in ovarian cancer. Science Immunology , 2025; 10 (107) DOI: 10.1126/sciimmunol.adr4795 Cite This Page : ...

Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting. PR Newswire. SAN JOSE, May 12, 2025.

2025 ASCO Presentation: Innovent Biologics Announces Updated Data of IBI354 (Novel anti-HER2 ADC) From the Phase 1/2 Clinical Study in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors.